Verified employee & interview reviews

Novartis India Reviews

Hyderabad, Telangana

—/ 5

0 reviews

Novartis India Limited (NIL), established in December 1947 and headquartered in Mumbai, Maharashtra, is a prominent pharmaceutical public limited company. It operates as a subsidiary of the Swiss multinational pharmaceutical giant Novartis AG, which maintains a controlling interest in the company. Spanning a history that connects back to predecessor entities Geigy, Ciba, and Sandoz, Novartis India serves as a critical component of the national healthcare infrastructure, primarily focusing on making high-quality therapeutic solutions accessible to patients across the Indian market. The company operates under a single consolidated business segment focused entirely on the wholesale trading and distribution of pharmaceutical products and medical goods. Novartis India focuses its therapeutic portfolio on major segments including bone and pain management, transplantation immunology, neurosciences, and oncology. Rather than maintaining heavy capital infrastructure, Novartis India utilizes an asset-light trading model. The entity does not own or operate dedicated manufacturing plants locally; instead, it imports finished dosage forms and advanced medications directly from global parent sources. It effectively manages nationwide distribution through three primary corporate offices, utilizing an expansive logistical network to supply commercial distributors, private hospital chains, and public government healthcare institutions across 22 Indian states. Its registered corporate office is situated at the Bandra Kurla Complex (BKC) in Mumbai. Financially, Novartis India Limited is publicly traded on the Bombay Stock Exchange (BSE) under the scrip code 500672 and the National Stock Exchange (NSE) under the ticker NOVARTIND. For the fiscal year ending March 31, 2025, the company generated a revenue from operations of INR 398 crore (approximately USD 40.1 million), delivering a Profit After Tax (PAT) of INR 100.9 crore. The trading business remains completely targeted toward the national domestic market, accounting for 100% of its operating product sales with 0% contribution originating from international export activities. Administratively, Novartis India operates with a lean corporate team size consisting of roughly 60 permanent employees. The company's governance structure is led by a board of directors that features Chairperson Christopher David Snook alongside Whole-time Director and Chief Financial Officer Shilpa Joshi. While Novartis India Limited manages the listed commercial trading footprint, the parent company also maintains a separate unlisted entity, Novartis Healthcare Private Limited (NHPL), which handles large-scale global drug development, clinical trial design, and regulatory operations out of major facilities in Hyderabad. Through strategic portfolio optimization, Novartis India continues to align with its broader global purpose of leveraging therapeutic innovation and medical accessibility to enhance, improve, and extend the quality of human life across the region.